Galera Therapeutics Inc. completed a $37 million series B designed to propel its pipeline of selective dismutase mimetics and move lead candidate, GC4419, into a randomized, double-blind phase IIb trial aimed to prevent oral mucositis (OM) in head and neck cancer patients receiving chemoradiation therapy.